COVID-19 Vaccine Information & Updates, click here »
COVID-19 Recorded Update Line: 402-504-6215

December 2020

Update 12-18-20:

We are preparing for the COVID-19 vaccination and details are rapidly developing. Please see Frequently Asked Questions (FAQs) flyer for more information about the vaccine. Our campus is registered for the vaccine, which includes the nursing home and all staff.

What we know from the state of Nebraska.

There are 3 phases:

Phase 1

• Potentially limited supply of COVID-19 vaccine doses available means that segments of the population must be prioritized to receive the vaccine.
• Vaccine type, dose lot size, and opportunity should influence local COVID-19 providers when phase population progression is necessary.

➢ Phase 1A

• Healthcare personnel (hospitals, home health care, pharmacies, EMS, outpatient, public health)
• Long-term Care Facility residents and staff, early stages of supply should go ONLY to those staff providing direct patient care AND/OR are exposed to infectious materials.
• Initial supplies of vaccine should NOT go to:
• Administrative staff
• Staff working remotely
• Staff not in direct contact with COVID patients or infectious materials

➢ Phase 1B
• First responders
• Education sector
• Food/Agricultural
• Utilities
• Transportation

➢ Phase 1C
• 65 years of age
• Vulnerable populations (disabled, homeless, etc)
• Congregate settings (incarcerated, colleges/universities, etc)

Phase 2

• Large number of vaccine doses available, sufficient to meet the demand of general population.
• Adhere to all applicable Centers for Medicare & Medicaid (CMS) COVID-19 testing requirements for LTCF staff.

Walgreens – Community Pharmacy will be our provider of the COVID-19 Vaccine for residents and staff. At this time we do not know when the clinics will be on-site.

Maple Crest is preparing for these clinics by doing the following:

• Staying engaged and current with our providers, local health department, and the state
• Working with Community Pharmacy about their timeline for the clinics
• Planning on assigning staff to assist pharmacy with the vaccination clinic
• Planning on dates when the vaccine clinics will be held
• Planning on staffing strategies to ensure we have adequate staff
• Calling families and updating them when we are informed when our clinic days will be

ABHM has set up a designated email address to best respond to any questions, comments, or concerns specifically related to the COVID-19 vaccine. COVID-19Vaccine@abhomes.org

 


 

Residents, Staff and Families,

There have been a lot of questions, comments and concerns from residents, families, employees, and those in our communities about the COVID-19 Vaccine. This vaccine is important in saving lives and reducing the transmissions of the virus.

The Food and Drug Administration (FDA) is actively reviewing the COVID-19 vaccine for Emergency Use Authorization in the United States.  ABHM operates in six states and those states have told the Centers for Disease Control (CDC) they want nursing home/assisted living providers to be a priority.

ABHM’s mission is to create caring Christian communities that empower older adults, families, and people with disabilities and receiving this vaccine for our residents, members, and staff is a priority.  We, as an organization, support the federal vaccine effort for COVID-19.

It is important residents, members, staff, and families know that ABHM has registered, on behalf of all of our nursing homes, assisted living communities, and homes for the developmentally disabled to receive the COVID-19 vaccine that the federal government will be disbursing in the near future. Please note, this does include all of our employees working at all of our locations across ABHM.

Distribution of the vaccine has yet to be determined.

Individual states will decide how to roll this large initiative in the healthcare sector

We will use our ABHM website, each community’s website, Facebook pages, and other methods to communicate changes and updates as they occur.

ABHM has set up a designated email address to best respond to any questions, comments, or concerns specifically related to the COVID-19 vaccine.

COVID-19Vaccine@abhomes.org

It is our duty to stay focused on our residents, members, staff and loved ones during this time of uncertainty. All of us have been impacted by the pandemic but we will continue to persevere. We urge you to join us in getting the COVID-19 vaccine, influenza vaccine, wear masks, avoid large gatherings, and stay six feet apart-especially through the holidays.

Thank you for your understanding, kindness, and prayers for those we serve.

There will be more information related to the vaccine as it is released by the government.

Stay Safe!

Jeff Hongslo
ABHM President/CEO

Continue reading...

ABHM Covid-19 Vaccine Information Video

(Click image above to view video)

ABHM is very excited about the COVID-19 vaccine coming to our communities.

Each community will receive the COVID-19 vaccine as soon as each state sets up their own vaccination process.

Although ABHM is not requiring staff to get vaccinated, we strongly encourage all employees to get the vaccination. Not only to safeguard your own health but to ensure the health and safety of everyone.

We realize some individuals may be apprehensive about getting the vaccination and have questions on how the vaccine works as well as side effects. Here is a link to a video message from Dr. Sing Palat, MD addressing some of the concerns regarding the vaccine.  https://vimeo.com/493717413

Sing Palat, MD, is an internist and geriatrician of 14 years and is a certified medical director.  As an associate of LTC Rehab Consultants, she provides care in nursing facilities and currently collaborates with Mountain Vista medical director Dr. Reza Esfahani on the COVID-19 response.   Dr. Palat is on the Board of CMDA The Colorado Society of Post-acute and Long-term Care.

If you have any further questions, do not hesitate to email us at COVID-19Vaccine@abhomes.org

 


Update 12-31-20:

We are preparing for the COVID-19 vaccination and details are rapidly developing. Our campus is registered for the vaccine, which includes the nursing home and all staff. 

As a reminder, Phase 1A is as follows:

➢Phase 1 A 

• Healthcare personnel (hospitals, home health care, pharmacies, EMS, outpatient, public health) 

• Long-term Care Facility residents and staff, early stages of supply should go ONLY to those staff providing direct patient care AND/OR are exposed to infectious materials.

• Initial supplies of vaccine should NOT go to:
• Administrative staff
• Staff working remotely
• Staff not in direct contact with COVID patients or infectious materials

Community Pharmacy will be our provider of the COVID-19 Vaccine for residents and staff. 


Maple Crest Update:

➢ Maple Crest was one of the first Nursing Homes in Omaha, NE to get the vaccine for residents and staff. 

➢ We were allotted the Pfizer vaccine by the state. 

➢ Our first clinic was on 12/28/2020.
• The clinic was run by Community Pharmacy in conjunction with Maple Crest staff. The pharmacy provided all supplies for the vaccine and Maple Crest provided the manpower. 

➢ Two more clinics are scheduled 21 days apart and are set for:
• January 18, 2021
• February 8, 2021

➢Our goal is to vaccinate all residents and staff that are eligible. 

• The resident participation rate was around 85%. Some residents want to wait until the second clinic to get the vaccine.

• At this time, the vaccine is voluntary for staff as well. The staff participation rate was 25%. Like the residents, some employees want to wait until the second clinic.

➢ We continue to provide education to staff and residents and encourage them to receive the vaccine.

 

ABHM has set up a designated email address to best respond to any questions, comments, or concerns specifically related to the COVID-19 vaccine. COVID-19Vaccine@abhomes.org

 


 

COVID-19 Vaccine Frequently Asked Questions

Is the vaccine safe?

The Advisory Committee on Immunization Practices (ACIP) and the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC)] review vaccine safety data. For COVID-19, ACIP has formed a separate Vaccine Safety Technical (VaST) to provide timely evaluation of vaccine safety, both pre- and post-licensure.

The Centers for Disease Control (CDC) is adding further monitoring programs to health care workers to analyze results six weeks after vaccination. Long-term Care is required to report all vaccinations through the National Healthcare Safety Network (NHSN). Most adverse side effects occur within six weeks of vaccine administration, and the FDA has required eight weeks of safety monitoring so it can track any side effects. FDA advises a minimum of 3,000 participants to assess safety. The current phase 3 trials have 30,000 to 50,000 participants. This really demonstrates how safety is a top priority for the FDA and the medical community.

Is ABHM requiring employees and their residents to take the vaccine?

Staff and residents are not required to take the vaccine.

Will personal protective equipment (PPE) guidelines be relaxed if the staff, residents and members are vaccinated?

Until ABHM knows the effectiveness of the vaccine, PPE guidelines will not be relaxed.

Is the vaccine one dose or a series?

The two initial vaccines projected for release are two-dose series vaccines and are not interchangeable. It’s important you schedule your second dose while getting your first dose because your booster must be from the same manufacturer.

Why can’t I have the vaccine now when others are receiving it?

At this time, there is not enough vaccine for everyone requesting it. Our state health departments are working with Walgreens or CVS to distribute the vaccine to those most at risk, including those living in long-term care facilities. The best way to prevent COVID-19 is by wearing a mask, practicing social distancing and washing your hands frequently.

If I already contracted COVID-19, do I need a vaccination?

ABHM is recommending all residents and employees get the COVID-19 vaccine, regardless of whether they have recovered from a previous COVID-19 infection. According to the CDC, there is not enough information currently available to say if or for how long after infection someone is protected from getting COVID-19 again. This is called natural immunity. Early evidence suggests natural immunity from COVID-19 may not last very long, but more studies are needed for a better understanding.

Does insurance cover the vaccine?

Private health insurance companies, as well as government insurance programs like Medicare, will cover the vaccination cost. You will need to have your insurance information when getting your vaccine.

 


 

COVID-19 Vaccine: Is It for You?

Travis LaCore, PharmD, BCGP, NREMT, FF2. ABHM Subject Matter Expert of Pharmacy

A COVID-19 vaccine has the potential to bring the pandemic to an end at a greater speed than any other intervention available. Vaccination will provide protection to an individual and reduce the chances of spreading as more people get the vaccine.

Despite the potential benefit of the COVID-19 vaccine to drastically reducing the spread of infection, there remains a high level of apprehension among the public regarding the safety of the vaccine. Although the development of a COVID-19 vaccine has been rapid, the research and development on a coronavirus vaccine is not new, nor are the methods used to produce the vaccine. The vaccine approval process also remains fundamentally unchanged and must include strong evidence of vaccine safety and effectiveness. Research and development of coronavirus vaccines date as far back to 2002 and 2012, SARS (Severe Acute Respiratory Syndrome) outbreak of 2002, and MERS (Middle Eastern Respiratory Syndrome) outbreak of 2012. Researchers’ directed the development of the COVID-19 vaccine utilizing the prior research on these outbreaks. One type of vaccine being developed, the mRNA vaccine, is a type of vaccine that has not been used in the US vaccine market previously, however it has been researched for decades in other areas such as cancer treatments.

The Pfizer BioNTech COVID-19 vaccine is a 2-dose series, with an estimated effectiveness rate of 95% at 28 days after the initial dose. The most common adverse reactions reported were injection site reaction, fatigue, headache, muscle pain, chills, joint pain, and fever, which are common reactions with any vaccine.

The next COVID-19 vaccine to be considered for an FDA EUA is the Moderna COVID-19 vaccine, which is scheduled to be reviewed by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) on December 17, 2020.

For questions and concerns about the vaccines, please contact your health care provider.

Continue reading...